NASDAQ:EXEL - Exelixis Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $33.10
  • Forecasted Upside: 91.11 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$17.32
▲ +0.29 (1.70%)

This chart shows the closing price for EXEL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Exelixis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EXEL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EXEL

Analyst Price Target is $33.10
▲ +91.11% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Exelixis in the last 3 months. The average price target is $33.10, with a high forecast of $52.00 and a low forecast of $26.00. The average price target represents a 91.11% upside from the last price of $17.32.

This chart shows the closing price for EXEL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 contributing investment analysts is to buy stock in Exelixis. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/31/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/29/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/27/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/27/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/26/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/24/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/23/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/22/2022

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/19/2021Piper SandlerInitiated CoverageOverweight$34.00High
11/3/2021Royal Bank of CanadaLower Price TargetOutperform$32.00 ➝ $31.00High
11/3/2021HC WainwrightLower Price TargetBuy$65.00 ➝ $52.00High
11/2/2021OppenheimerLower Price TargetOutperform$30.00 ➝ $29.00Medium
10/6/2021Jefferies Financial GroupInitiated CoverageBuy$28.00Medium
9/20/2021HC WainwrightReiterated RatingBuy$65.00Low
9/20/2021Truist FinancialLower Price TargetBuy$37.00 ➝ $36.00High
9/9/2021HC WainwrightReiterated RatingBuy$65.00Low
8/6/2021HC WainwrightBoost Price TargetBuy$35.00 ➝ $64.00High
6/29/2021HC WainwrightReiterated RatingBuy$47.00 ➝ $35.00Low
6/29/2021OppenheimerLower Price TargetOutperform$35.00 ➝ $27.00Medium
6/28/2021Needham & Company LLCLower Price TargetBuy$33.00 ➝ $30.00High
6/15/2021HC WainwrightInitiated CoverageBuy$47.00Medium
4/19/2021Morgan StanleyLower Price TargetEqual Weight$27.00 ➝ $26.00Low
3/30/2021Credit Suisse GroupInitiated CoverageOutperform$30.00High
3/11/2021Wolfe ResearchInitiated CoverageOutperform$35.00Medium
2/16/2021Piper SandlerBoost Price TargetOverweight$33.00 ➝ $36.00Low
1/15/2021William BlairReiterated RatingBuyN/A
12/16/2020Morgan StanleyLower Price TargetEqual Weight$29.00 ➝ $27.00Low
10/26/2020Stifel NicolausBoost Price TargetHold$26.00 ➝ $27.00Low
9/22/2020Morgan StanleyBoost Price TargetEqual Weight$23.00 ➝ $29.00Low
9/21/2020OppenheimerBoost Price TargetOutperform$33.00 ➝ $37.00Low
9/21/2020Piper SandlerBoost Price TargetOverweight$30.00 ➝ $33.00High
8/14/2020William BlairReiterated RatingBuyHigh
8/7/2020Morgan StanleyBoost Price TargetEqual Weight$22.00 ➝ $23.00Medium
7/15/2020Morgan StanleyBoost Price TargetEqual Weight$21.00 ➝ $22.00Low
7/8/2020SunTrust BanksReiterated RatingBuy$40.00Low
6/2/2020William BlairReiterated RatingBuyMedium
6/1/2020OppenheimerInitiated CoverageBuy$28.00 ➝ $32.00Medium
5/14/2020SunTrust BanksBoost Price TargetPositive ➝ Buy$35.00 ➝ $40.00High
5/6/2020BMO Capital MarketsBoost Price TargetMarket Perform$20.00 ➝ $27.00Medium
5/6/2020Needham & Company LLCReiterated RatingBuy$33.00Medium
5/6/2020Piper SandlerBoost Price Target$23.00 ➝ $30.00Medium
5/6/2020Morgan StanleyBoost Price TargetEqual Weight$20.00 ➝ $21.00Low
4/21/2020GuggenheimBoost Price Target$27.00 ➝ $32.00High
4/21/2020BarclaysReiterated RatingBuy$30.00High
4/21/2020OppenheimerBoost Price TargetOutperform$25.00 ➝ $28.00High
4/20/2020Needham & Company LLCBoost Price TargetBuy$28.00 ➝ $33.00Medium
3/25/2020Piper SandlerReiterated RatingBuy$23.00High
3/13/2020William BlairReiterated RatingBuyLow
3/4/2020BarclaysInitiated CoverageOverweight$26.00Medium
2/27/2020Piper SandlerLower Price Target$35.00 ➝ $23.00Medium
2/26/2020BMO Capital MarketsBoost Price TargetMarket Perform$19.00 ➝ $20.00Medium
2/26/2020Stifel NicolausBoost Price TargetHold$21.00 ➝ $23.00Medium
2/26/2020CowenReiterated RatingBuyMedium
2/14/2020William BlairReiterated RatingBuyLow
2/11/2020Piper SandlerReiterated RatingBuy$35.00High
1/27/2020Needham & Company LLCReiterated RatingBuy$28.00Low
1/13/2020SunTrust BanksInitiated CoverageBuy$31.00High
1/13/2020Bank of AmericaReiterated RatingBuy$22.00 ➝ $21.00High
1/12/2020CowenReiterated RatingBuy$23.00Low
1/9/2020William BlairReiterated RatingBuyLow
12/13/2019Needham & Company LLCReiterated RatingBuy$30.00Low
12/13/2019CowenReiterated RatingBuy$23.00Low
11/13/2019Bank of AmericaInitiated CoverageBuy$22.00High
10/31/2019Piper Jaffray CompaniesLower Price Target$45.00 ➝ $35.00High
10/15/2019GuggenheimLower Price TargetBuy$33.00 ➝ $25.00High
10/8/2019BMO Capital MarketsLower Price TargetMarket Perform$23.00 ➝ $19.00Medium
8/1/2019Stifel NicolausBoost Price TargetHold$22.00 ➝ $23.00High
7/31/2019CowenSet Price TargetBuy$25.00N/A
7/15/2019CowenSet Price TargetBuy$25.00Medium
5/2/2019Morgan StanleySet Price TargetHold$27.00High
4/23/2019CowenReiterated RatingBuy$29.00High
3/19/2019OppenheimerReiterated RatingBuyLow
3/18/2019Morgan StanleyUpgradeUnderweight ➝ Equal Weight$24.80High
3/1/2019Piper Jaffray CompaniesReiterated RatingOverweight$48.00Low
2/26/2019CowenReiterated RatingBuy$29.00Low
2/22/2019BMO Capital MarketsInitiated CoverageMarket Perform$23.00Low
2/13/2019OppenheimerLower Price TargetOutperform$40.00 ➝ $31.00Low
11/15/2018OppenheimerSet Price TargetBuy$40.00Medium
11/5/2018Piper Jaffray CompaniesLower Price TargetOverweight$29.00 ➝ $26.00Low
11/1/2018OppenheimerSet Price TargetBuy$40.00High
9/17/2018GuggenheimInitiated CoverageBuyHigh
9/17/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$22.00High
9/10/2018Morgan StanleyInitiated CoverageUnderweight ➝ Underweight$19.00Medium
8/1/2018Stifel NicolausLower Price TargetHold ➝ Hold$29.00 ➝ $25.00Low
5/11/2018Needham & Company LLCLower Price TargetBuy ➝ Buy$33.00 ➝ $30.00High
5/10/2018Piper Jaffray CompaniesLower Price TargetOverweight$33.00 ➝ $29.00High
5/3/2018Stifel NicolausLower Price TargetHold ➝ Hold$30.00 ➝ $29.00High
4/11/2018William BlairReiterated RatingBuyLow
2/27/2018Stifel NicolausBoost Price TargetHold ➝ Hold$29.00 ➝ $30.00High
2/27/2018OppenheimerUpgradeMarket Perform ➝ Outperform$40.00High
2/27/2018UBS GroupUpgradeMarket Perform ➝ OutperformHigh
2/12/2018William BlairReiterated RatingOutperformMedium
1/17/2018OppenheimerReiterated RatingHoldHigh
1/4/2018OppenheimerReiterated RatingHoldMedium
12/21/2017SunTrust BanksReiterated RatingBuy$38.00High
12/19/2017OppenheimerReiterated RatingHoldLow
10/17/2017Needham & Company LLCBoost Price TargetBuy$30.00 ➝ $33.00N/A
10/17/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$33.00 ➝ $39.00N/A
10/17/2017Stifel NicolausReiterated RatingHold$26.00N/A
10/16/2017Piper Jaffray CompaniesReiterated RatingOverweightN/A
10/16/2017OppenheimerReiterated RatingHoldN/A
10/16/2017SunTrust BanksBoost Price TargetBuy ➝ Buy$32.00 ➝ $35.00N/A
10/2/2017Needham & Company LLCReiterated RatingBuy$30.00Low
9/25/2017OppenheimerReiterated RatingHoldMedium
9/22/2017SVB LeerinkDowngradeOutperform ➝ Market Perform$34.00 ➝ $28.00High
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$32.00Medium
9/12/2017Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00 ➝ $30.00Medium
9/10/2017OppenheimerReiterated RatingHoldMedium
9/10/2017Piper Jaffray CompaniesReiterated RatingBuy$29.00Medium
9/7/2017Stifel NicolausReiterated RatingHold$26.00Low
8/10/2017CowenReiterated RatingOutperformMedium
8/3/2017Piper Jaffray CompaniesReiterated RatingBuy$29.00Low
8/3/2017Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$26.00 ➝ $29.00Medium
8/3/2017Stifel NicolausReiterated RatingHold$26.00High
7/27/2017William BlairReiterated RatingOutperformMedium
7/13/2017SunTrust BanksInitiated CoverageBuy ➝ Buy$33.00Medium
6/26/2017William BlairReiterated RatingOutperformMedium
6/16/2017William BlairReiterated RatingOutperformLow
6/12/2017OppenheimerInitiated CoverageHoldLow
6/5/2017OppenheimerReiterated RatingHoldLow
5/4/2017OppenheimerReiterated RatingMarket PerformMedium
4/21/2017OppenheimerReiterated RatingMarket PerformHigh
3/31/2017Needham & Company LLCInitiated CoverageBuy ➝ Buy$28.00Medium
3/16/2017CIBCInitiated CoverageMarket Perform ➝ Market PerformHigh
3/16/2017OppenheimerInitiated CoverageMarket PerformHigh
3/1/2017William BlairReiterated RatingOutperformN/A
2/28/2017Stifel NicolausDowngradeBuy ➝ Hold$22.00N/A
1/28/2017William BlairReiterated RatingOutperformN/A
1/24/2017CowenReiterated RatingOutperformN/A
(Data available from 1/22/2017 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2021
  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 5 very negative mentions
7/26/2021
  • 7 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/25/2021
  • 5 very positive mentions
  • 10 positive mentions
  • 5 negative mentions
  • 12 very negative mentions
9/24/2021
  • 8 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2021
  • 7 very positive mentions
  • 24 positive mentions
  • 8 negative mentions
  • 2 very negative mentions
11/23/2021
  • 8 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/23/2021
  • 13 very positive mentions
  • 30 positive mentions
  • 2 negative mentions
  • 4 very negative mentions
1/22/2022

Current Sentiment

  • 13 very positive mentions
  • 30 positive mentions
  • 2 negative mentions
  • 4 very negative mentions

Recent Stories by Sentiment

Exelixis logo
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
Read More

Today's Range

Now: $17.32
Low: $16.86
High: $17.55

50 Day Range

MA: $17.77
Low: $15.84
High: $19.28

52 Week Range

Now: $17.32
Low: $15.50
High: $25.77

Volume

3,656,431 shs

Average Volume

2,160,845 shs

Market Capitalization

$5.48 billion

P/E Ratio

33.96

Dividend Yield

N/A

Beta

0.89

Frequently Asked Questions

What sell-side analysts currently cover shares of Exelixis?

The following Wall Street sell-side analysts have issued stock ratings on Exelixis in the last twelve months: Credit Suisse Group AG, HC Wainwright, Jefferies Financial Group Inc., Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, TheStreet, Truist Financial Co., Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for EXEL.

What is the current price target for Exelixis?

10 Wall Street analysts have set twelve-month price targets for Exelixis in the last year. Their average twelve-month price target is $33.10, suggesting a possible upside of 91.1%. HC Wainwright has the highest price target set, predicting EXEL will reach $52.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $26.00 for Exelixis in the next year.
View the latest price targets for EXEL.

What is the current consensus analyst rating for Exelixis?

Exelixis currently has 1 hold rating and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EXEL will outperform the market and that investors should add to their positions of Exelixis.
View the latest ratings for EXEL.

How do I contact Exelixis' investor relations team?

Exelixis' physical mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company's listed phone number is (650) 837-7000 and its investor relations email address is [email protected] The official website for Exelixis is www.exelixis.com.